

Date: May 16, 2021

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, The Manager, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
--	---

Sub: Disclosure of events or information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (“SEBI LODR Regulations”), we wish to inform you that on 15th May, 2021 the Shares Transfer/Administrative & Finance Committee (the “Committee”) of Camlin Fine Sciences Limited (the “Company”), pursuant to the powers granted by the Board of Directors, has approved strategic investment in AlgalR NutraPharms Private Limited (“AlgalR”) by way of acquisition of equity shares amounting to 69.33% of the existing paid-up share capital (“Secondary Purchase”). The Committee has also approved subscription to the equity shares of AlgalR (“Primary Subscription”). Upon consummation of the Secondary Purchase and Primary Subscription, the Company will hold 80% of the paid-up capital of AlgalR on a fully diluted basis. The Company will now be executing the Investment Agreement, Share Purchase Agreement and the incidental agreements / documents with AlgalR and its promoters / other shareholders.

The details required under SEBI LODR Regulations are annexed herewith.

We request you to kindly take the above on record.

Thanking you,

For Camlin Fine Sciences Limited



Mandar Godbole
Company Secretary &
General Manager - Legal

 Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

 +91 22 6700 1000

 +91 22 2832 4404

 corporate@camlinfs.com

 www.camlinfs.com

Annexure

Sr. No.	Particulars	Details
a.	Name of the target entity	AlgalR NutraPharms Private Limited ("AlgalR")
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group companies have any interest in the entity being acquired	The acquisition does not fall within related party transaction(s). The promoter / promoter group have no interest in AlgalR.
c.	Industry to which the entity being acquired belongs	Nutraceuticals and Pharma
d.	Objects and Effects of acquisition	AlgalR provides an opportunity to the Company for expanding its footprint into the Nutraceuticals segment. Upon completion of the acquisition, the Company shall become the holder of 80% of the paid-up share capital of AlgalR on a fully diluted basis.
e.	Brief details of any governmental regulatory approvals required for the acquisition	None
f.	Indicative time period for completion of acquisition	Within 30 days
g.	Nature of consideration (Cash Consideration or Share Swap and details of the same	Cash
h.	Cost of acquisition or the price at which the shares are acquired	INR 70/- per equity share.
i.	Percentage of Shareholding/control acquired and/or number of shares acquired	The Company will be acquiring 80% of the issued and paid-up share capital of AlgalR on a fully diluted basis.
j.	Brief background about the entity acquired in terms of products/line of business acquired, history of last 3 years turnover, country in which the acquired entity has presence.	AlgalR was incorporated on 24 th July 2014. It is a manufacturer of Algal Omega-3 fatty acids, particularly Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) from microalgae, which are considered 100% Vegetarian. Omega-3 fatty acids play an important role in the human metabolism and has been associated with a number of


Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

		health benefits. These products are manufactured in compliance with the set industrial norms, FSSAI, and ISO 22000:2005 standards using a patented technology in a state-of-the-art production system located in Southern part of India. Revenue from operations for the past 3 years: FY 2020-21: INR 59,10,754/- FY 2019-20: INR 55,60,392/- FY 2018-19: INR 4,43,250/-
--	--	--

For Camlin Fine Sciences Limited




Mandar Godbole
Company Secretary &
General Manager - Legal

 **Registered Office:**
Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

 +91 22 6700 1000

 +91 22 2832 4404

 corporate@camlinfs.com

 www.camlinfs.com